Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

47results about How to "Useful in practice" patented technology

Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use

The present invention relates to pharmaceutical compositions for the sustained release of pharmacologically active compounds and methods of their manufacture and use. Sustained release times of 10-12 days have been achieved with the present invention. The present invention provides microcrystal compositions. The microcrystals comprise pharmacologically active compounds and are contained within a phospholipid layer which contains a unique combination of phospholipids. The present invention may be applied to a wide range of pharmaceutical compositions which may be rendered suitable for injection. The microcrystals are of varying sizes. At least 50 percent of the microcrystals are from 0.5 mum to about 3.0 mum in diameter, at least ten percent of the microcrystals are from about 3.0 mum to about 10 mum in diameter, and the composition contains microcrystals which are greater than 10 mum in diameter. In preferred embodiments, at least about 1% of the microcrystals are greater than 10 mum in diameter. The compositions and methods are useful for treating respiratory diseases, infections, inflammation, and pain in a variety of mammals. The compounds and methods are also able to sharply reduce the toxicity of drug compounds.
Owner:IDEXX LABORATORIES +1

Group key exchanges with failures

Described are a method for generating a session key on demand in a network, a computer program element, a computer program product stored on a computer usable medium, and a computer device for executing the computer program product. The method generates a session key sk on demand in a network among n participating network devices with up to a number t of faulty devices. Each participating network device sends and receives a series of messages and performs the steps of: a) choosing a private and public key di, ei according to a public key encryption scheme, and broadcasting the public key ei to each participating network device; b) choosing a local contribution value yi from a multiplicative group Gq of size q; c) in each case of receiving the public key ej from one of the participating network devices, encrypting the local contribution value yi under the received public key ej to an encrypted contribution value yij and responding to the one participating network device the encrypted contribution value yij; d) receiving encrypted contribution values yji and deriving decrypted contribution values yj by applying the private key di; e) deriving a blinded session key bski from the decrypted contribution values yj and the local contribution value yi; f) agreeing on one of the blinded session keys bskj by using an agreement protocol; and g) deriving the session key sk from the agreed-on blinded session key bskj by applying one of the decrypted contribution values yj and the contribution value yi.
Owner:IBM CORP

Apolactoferrin Compositions and Methods for Their Use in the Treatment of Viral Hepatitis C

InactiveUS20090142298A1Low costHighly effective in treatingPeptide/protein ingredientsMetabolism disorderDiseaseApoptosis
The invention refers to medicine, in particular to hepatology and virology, and can be used for treatment, including complete recovery, of patients with viral hepatitis C, including its chronic form. This invention provides a remedy for treating viral hepatitis C, that is, apoprotein lactoferrin in a monomeric form. This invention also refers to a pharmaceutical composition for treating viral hepatitis C that contains a therapeutically effective amount of apoprotein lactoferrin in a monomeric form and a pharmaceutically acceptable vehicle, filler or excipient. This invention also refers to a pharmaceutical composition for treating viral hepatitis C that includes administration of apoprotein lactoferrin in a monomeric form and to using apoprotein lactoferrin in a monomeric form for manufacturing a medication for treating viral hepatitis C. The treatment method of this invention allows to prevent virus viremia completely as a result of two or three weeks treatment, to prevent destruction of hepatocytes, affected with hepatitis C virus, together with the emission of additional number of viruses to the blood circulation system and to end the existence of the affected with virus hepatocytes with apoptosis, thus, preventing the development of hepatosis, cirrhosis and oncological damage to the liver, being the terminal stage of the main disease development.
Owner:SHATUNOVSKIY NIKOLAY E
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products